信立泰涨2.14%，成交额2.47亿元，主力资金净流入257.52万元

Core Viewpoint - The stock of Shenzhen Sinopharm Co., Ltd. (信立泰) has shown significant growth in 2023, with a year-to-date increase of 88.14%, reflecting strong market performance and investor interest [1][2]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 3.241 billion yuan, representing a year-on-year growth of 8.00% [2]. - The net profit attributable to shareholders for the same period was 581 million yuan, marking a year-on-year increase of 13.93% [2]. Stock Market Activity - As of October 28, 2023, the stock price reached 57.25 yuan per share, with a trading volume of 2.47 billion yuan and a turnover rate of 0.39% [1]. - The stock has been active on the market, appearing on the "龙虎榜" (top trading list) twice this year, with the most recent instance on June 17, 2023, where it recorded a net buy of -41.9885 million yuan [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 25,200, up by 4.87% from the previous period [2]. - The top shareholders include 中欧医疗健康混合A (003095) and 香港中央结算有限公司, with significant increases in their holdings [3]. Dividend Distribution - Since its A-share listing, the company has distributed a total of 7.204 billion yuan in dividends, with 1.649 billion yuan distributed over the past three years [3].